I-Corps: Tailored Amorphous Multi-Porous (TAMP) Bioactive Scaffolds for Tissue Regeneration

组织工程通过刺激身体再生缺陷部分，为功能失调的组织或器官提供了一种优越的治疗方法。这种用于硬组织（骨和牙齿）的首选治疗方法需要一种生物支架，它必须理想地具有：(a)生物相容性；(b)与组织生长相匹配的生物降解性；(c)高度互联的大孔(100？S（微米）促进细胞长入、血管形成和营养输送；(d)叠加纳米孔隙，引导细胞附着、迁移和分化；(e)催化再生过程的生物活性。市场上没有任何合成产品能满足所有这些要求，包括生物活性玻璃（BG）——唯一一种用于硬组织再生的人工促骨材料。这个I-Corps团队开发了一种制造新型生物活性材料的技术。与竞争产品（包括目前市场上基于生物活性玻璃的产品）相比，所提出的技术具有优异的骨诱导性和优越的可降解性。它使人们能够根据特定的患者类型和缺陷的性质来定制支架的降解行为，而不影响组织的生长。I-Corps团队通过将相互连接的纳米孔叠加在大孔上，采用新颖的制造方法解决了上述挑战：大孔为组织向内生长提供基本基质，纳米孔增强细胞反应，以及定制支架的能力。S降解率。结果是一种新的制造技术组合，用于生产“定制无定形多孔（TAMP）”支架，以满足特定患者类型的需求。体外和体内试验已经证明了改善牙科和骨科患者治疗的原理证明和潜力。TAMP制造技术可以很容易地应用于具有额外功能的新型BG组合物，例如抗菌和抗龋性能。当延伸到纤维形式时，这些TAMP结构具有机械柔韧性。因此，TAMP材料技术已经做好了商业化的准备。

Tissue engineering is providing a superior treatment for dysfunctional tissues or organs by stimulating the body to regenerate anew the defective part. This preferred treatment, yet to be established for hard tissue (bone and teeth), requires a bioscaffold, which must ideally have: (a) biocompatibility; (b) biodegradability that matches tissue growth; (c) highly interconnected macropores (100?s of microns) to promote ingrowth of cells, vascularization and nutrient delivery; (d) superimposed nanoporosity to guide cell attachment, migration and differentiation; and (e) bioactivity to catalyze the regeneration process. No synthetic product in the market satisfies all these requirements, including bioactive glass (BG) - the only manmade osteo-stimulating material for hard tissue regeneration. This I-Corps team has developed technology for fabricating a new class of bioactive material. The proposed technology provides excellent osteoinductivity and superior degradability compared to competing products, including those based on bioactive glass in the current market. It gives one the ability to tailor the degradation behavior of the scaffolds to specific patient types and nature of the defects without compromising the tissue growth. This I-Corps team has resolved the above challenges by introducing interconnected nanoporosity superimposed on macroporosity using novel fabrication methods: macroporosity to provide a basic substrate for tissue ingrowth, nanoporosity to enhance cell response and, the ability to tailor the scaffold?s degradation rate. The result is a novel fabrication technology portfolio for producing 'tailored amorphous multi-porous (TAMP)' scaffold that is matched to the needs of specific patient types. In vitro and in vivo tests have already demonstrated the proof-of-principle and potential for improved treatment of dental and orthopedic patients. The TAMP fabrication technology can be readily applied to new BG compositions with additional functionality such as antibacterial and anti-caries properties. When extended to fiber form, these TAMP structures are mechanically flexible. Thus, TAMP material technology is well poised for commercialization.